Scarica l'app Stockscreener
84.52
1.32%
1.10
Dopo l'orario di chiusura:
84.49
-0.03
-0.04%
Precedente Chiudi:
$83.42
Aprire:
$84.81
Volume 24 ore:
586.39K
Relative Volume:
0.59
Capitalizzazione di mercato:
$5.60B
Reddito:
-
Utile/perdita netta:
$-116.25M
Rapporto P/E:
-35.35
EPS:
-2.3912
Flusso di cassa netto:
$-91.19M
1 W Prestazione:
+0.07%
1M Prestazione:
-7.76%
6M Prestazione:
+58.54%
1 anno Prestazione:
+340.67%
Intervallo 1D:
$83.33
$86.00
Intervallo di 1 settimana:
$81.11
$86.51
Portata 52W:
$19.04
$115.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
84.52 | 5.59B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Form 144 Oruka Therapeutics For: 1 October By Investing.com - Investing.com Canada
25,000 shares from a stock-option exercise are proposed for sale at Oruka Therapeutics (NASDAQ: ORKA). - Stock Titan
ETFs Investing in Oruka Therapeutics, Inc. Stocks - TradingView
Average basic shares outstanding of Oruka Therapeutics, Inc. – HAN:HQ1 - TradingView
HQ1 Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Oruka Therapeutics For: 27 September By Investing.com - Investing.com South Africa
Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history - Yahoo Finance Singapore
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says - Yahoo Finance
Oruka Therapeutics, Inc. (ORKA) Stock Price, News, Quote & History - Yahoo! Finance Canada
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - Yahoo Finance
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $175 - Moomoo
Oruka Therapeutics stock price target maintained at $120 by H.C. Wainwright - Investing.com Canada
Oruka Therapeutics stock falls despite positive trial data - Investing.com
Clear Street Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $131 - Moomoo
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders - Yahoo Finance
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001 - marketscreener.com
Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001 - Yahoo Finance
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Oruka posts trial data for plaque psoriasis drug (ORKA:NASDAQ) - Seeking Alpha
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy - AOL.com
Why is Oruka Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28 - marketscreener.com
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data - Yahoo Finance
Oruka Therapeutics stock falls despite positive trial data By Investing.com - Investing.com Australia
Oruka reports week 28 psoriasis trial results for ORKA-001 By Investing.com - Investing.com Canada
Oruka reports week 28 psoriasis trial results for ORKA-001 - Investing.com
In a psoriasis trial, 71% had clear skin six months after their last dose - Stock Titan
Oruka Therapeutics general counsel Paul Quinlan sells $936k in stock - Investing.com Nigeria
Form 4 Oruka Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Oruka Therapeutics Inc For: 22 September - Investing.com UK
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock By Investing.com - Investing.com Australia
Details on Warrant Exercise and Subsequent Share Sales by Oruka Therapeutics' General Counsel - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal Sells 533 Shares Under Rule 10b5-1 Plan - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock - Investing.com
Oruka Therapeutics Insider Sold Shares Worth $936,417, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics (NASDAQ: ORKA) insider plans new share sale after recent 10b5-1 trades - Stock Titan
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175 - Moomoo
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire
Oruka Therapeutics COO Sandler sells $86,713 in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock - Investing.com Canada
Oruka Therapeutics CEO Lawrence Klein sells $234,680 in ORKA stock - Investing.com
Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares - Investing.com UK
Oruka Therapeutics general counsel Paul Quinlan sells $99,442 in stock By Investing.com - Investing.com Canada
Oruka Therapeutics general counsel Paul Quinlan sells $99,442 in stock - Investing.com UK
Oruka Therapeutics COO Sandler sells $86,713 in common stock - Investing.com
Oruka Therapeutics CEO Lawrence Klein Executes 2,452-Share Sale for RSU Tax Withholding - Kalkine Media
Oruka Therapeutics SVP Finance Arjun Agarwal Reports Multiple Stock Option Exercises and Sales - Kalkine Media
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oruka Therapeutics Inc Azioni (ORKA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Agarwal Arjun | Senior Vice President, Finance |
Sep 21 '26 |
Sale |
95.75 |
533 |
51,035 |
14,219 |
| Quinlan Paul T | General Counsel |
Sep 21 '26 |
Option Exercise |
7.80 |
10,000 |
78,000 |
39,995 |
| Quinlan Paul T | General Counsel |
Sep 21 '26 |
Sale |
93.64 |
10,000 |
936,417 |
29,995 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):